Endocrinol Metab.  2016 Mar;31(1):93-99. 10.3803/EnM.2016.31.1.93.

High Levels of Serum DPP-4 Activity Are Associated with Low Bone Mineral Density in Obese Postmenopausal Women

• Kim SW
• Cho EH

• KMID: 2169698
• DOI: http://doi.org/10.3803/EnM.2016.31.1.93

Abstract

BACKGROUND
Dipeptidyl peptidase 4/CD26 (DPP-4) is a widely expressed cell surface serine protease. DPP-4 inhibitors, one of common anti-diabetic agents play a protective role in bone metabolism in recent studies. A soluble form of DPP-4 is found in serum, and exhibits DPP-4 enzymatic activity. However, the physiological role of serum or soluble DPP-4 and its relationship with DPP-4 enzymatic function remain poorly understood. The aims of current study were to determine the association between serum DPP-4 activity and bone mineral density (BMD) in postmenopausal women.
METHODS
We recruited data and serum samples from 124 consecutive healthy postmenopausal women aged >50 years. We divided study subjects into obese (body mass index [BMI] ≥25 kg/m2) and non-obese (BMI <25 kg/m2) postmenopausal women and examined the correlation between serum DPP-4 activity and clinical variables in each groups.
RESULTS
A total of 124 postmenopausal women was enrolled, with a mean age of 59.9±7.1 years. The mean BMI of the study patients was 24.4±2.8 kg/m2. Regarding bone turnover markers, serum DPP-4 activity was positively correlated with serum calcium concentrations, intact parathyroid hormone, and serum C-telopeptide levels in all of the study subjects. However, there was no association between serum DPP-4 activity and BMD in the spine or femoral neck in all of the study subjects. Serum DPP-4 activity was negatively correlated (R=−0.288, P=0.038) with BMD of the spine in obese postmenopausal women.
CONCLUSION
This study demonstrated for the first time that serum soluble DPP-4 activity was negatively correlated with BMD in obese postmenopausal women.

Keyword

Dipeptidyl peptidase 4; Bone mineral density; Postmenopause; Women

MeSH Terms

Biological Markers
Bone Density*
Calcium
Dipeptidyl Peptidase 4
Female
Femur Neck
Humans
Metabolism
Parathyroid Hormone
Postmenopause
Serine Proteases
Spine
Biological Markers
Calcium
Dipeptidyl Peptidase 4
Parathyroid Hormone
Serine Proteases

Figure

• 

  Fig. 1 Correlation analysis showing the association between bone mineral density and serum dipeptidyl peptidase 4/CD26 (DPP-4) activity levels in obese postmenopausal women (n=52). BMD, bone mineral density.

Reference

1. Sattui SE, Saag KG. Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol. 2014; 10:592–602.

2. de Meester I, Lambeir AM, Proost P, Scharpe S. Dipeptidyl peptidase IV substrates. An update on in vitro peptide hydrolysis by human DPPIV. Adv Exp Med Biol. 2003; 524:3–17.

3. Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003; 40:209–294.

4. Polgar L, Szabo E. Prolyl endopeptidase and dipeptidyl peptidase IV are distantly related members of the same family of serine proteases. Biol Chem Hoppe Seyler. 1992; 373:361–366.

5. Pala L, Rotella CM. The role of DPP4 activity in cardiovascular districts: in vivo and in vitro evidence. J Diabetes Res. 2013; 2013:590456.

6. Dicembrini I, Mannucci E, Rotella CM. Bone: incretin hormones perceiver or receiver? Exp Diabetes Res. 2012; 2012:519784.

7. Glorie L, Behets GJ, Baerts L, De Meester I, D'Haese PC, Verhulst A. DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats. Am J Physiol Endocrinol Metab. 2014; 307:E447–E455.

8. Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care. 2011; 34:2474–2476.

9. Henriksen DB, Alexandersen P, Hartmann B, Adrian CL, Byrjalsen I, Bone HG, et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone. 2009; 45:833–842.

10. Durinx C, Lambeir AM, Bosmans E, Falmagne JB, Berghmans R, Haemers A, et al. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem. 2000; 267:5608–5613.

11. Lee SA, Kim YR, Yang EJ, Kwon EJ, Kim SH, Kang SH, et al. CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013; 98:2553–2561.

12. Iwaki-Egawa S, Watanabe Y, Kikuya Y, Fujimoto Y. Dipeptidyl peptidase IV from human serum: purification, characterization, and N-terminal amino acid sequence. J Biochem. 1998; 124:428–433.

13. Cordero OJ, Salgado FJ, Nogueira M. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother. 2009; 58:1723–1747.

14. Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens DM, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011; 60:1917–1925.

15. Cho EH, Cho KH, Lee HA, Kim SW. High serum osteopontin levels are associated with low bone mineral density in postmenopausal women. J Korean Med Sci. 2013; 28:1496–1499.

16. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care. 2007; 30:1335–1343.

17. Abbott CA, Baker E, Sutherland GR, McCaughan GW. Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene. Immunogenetics. 1994; 40:331–338.

18. Walsh JS, Henriksen DB. Feeding and bone. Arch Biochem Biophys. 2010; 503:11–19.

19. Driessen JH, van Onzenoort HA, Henry RM, Lalmohamed A, van den Bergh JP, Neef C, et al. Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture. Bone. 2014; 68:124–130.

20. Gallagher EJ, Sun H, Kornhauser C, Tobin-Hess A, Epstein S, Yakar S, et al. The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes. Diabetes Metab Res Rev. 2014; 30:191–200.

21. Huber BC, Brunner S, Segeth A, Nathan P, Fischer R, Zaruba MM, et al. Parathyroid hormone is a DPP-IV inhibitor and increases SDF-1-driven homing of CXCR4(+) stem cells into the ischaemic heart. Cardiovasc Res. 2011; 90:529–537.

22. Grabmaier U, Brandl L, Kreiner J, Negele T, Huber BC, Rimmbach C, et al. Increased numbers of bone marrow-derived cells in parathyroid adenoma. Eur J Clin Invest. 2014; 44:833–839.

23. Nishida H, Suzuki H, Madokoro H, Hayashi M, Morimoto C, Sakamoto M, et al. Blockade of CD26 signaling inhibits human osteoclast development. J Bone Miner Res. 2014; 29:2439–2455.

24. Zheng T, Yang L, Liu Y, Liu H, Yu J, Zhang X, et al. Plasma DPP4 activities are associated with osteoporosis in postmenopausal women with normal glucose tolerance. J Clin Endocrinol Metab. 2015; 100:3862–3870.

25. Kyle KA, Willett TL, Baggio LL, Drucker DJ, Grynpas MD. Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice. Endocrinology. 2011; 152:457–467.

26. Bunck MC, Poelma M, Eekhoff EM, Schweizer A, Heine RJ, Nijpels G, et al. Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients. J Diabetes. 2012; 4:181–185.